**Supplementary Table 1. Patients’ subjective bladder condition (full analysis set)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Placebo**  **(N=72)** | **DA-8010 2.5mg**  **(N=70)** | **DA-8010 5mg**  **(N=71)** | **Solifenacin 5mg**  **(N=72)** |
| **Patient Perception of Bladder Condition (PPBC)** |  |  |  |  |
| **Baseline** | 3.83±1.13 [4.00] | 4.00±1.02 [4.00] | 3.89±1.21 [4.00] | 3.74±1.22 [4.00] |
| **Change from Baseline at Week 4** | -0.60±1.15 [0.00] | -0.71±1.07 [-1.00] | -0.76±1.35 [-1.00] | -0.65±1.20 [-1.00] |
| LS Mean(SE) | -0.61(0.13) | -0.64(0.13) | -0.74(0.13) |  |
| P-value [1] |  | 0.8782 | 0.4576 |  |
| **Change from Baseline at Week 8** | -0.76±1.28 [-1.00] | -0.80±1.00 [-1.00] | -0.82±1.09 [-1.00] | -0.71±1.29 [-1.00] |
| LS Mean(SE) | -0.78(0.13) | -0.75(0.13) | -0.81(0.13) |  |
| P-value [1] |  | 0.8733 | 0.8625 |  |
| **Change from Baseline at Week 12** | -0.67±1.28 [-1.00] | -1.06±1.08 [-1.00] | -0.92±1.09 [-1.00] | -0.79±1.39 [-1.00] |
| LS Mean(SE) | -0.64(0.13) | -0.96(0.13) | -0.86(0.13) |  |
| P-value [1] |  | 0.0802 | 0.2234 |  |
| **Overactive Bladder Questionnaire (OAB-q) Symptom Severity** |  |  |  |  |
| **Baseline** | 44.68±22.76 [40.00] | 41.90±19.68 [36.67] | 45.40±20.18 [43.33] | 43.10±23.20 [40.00] |
| **Change from Baseline at Week 4** | -8.98±17.35 [-6.67] | -9.71±18.15 [-10.00] | -13.57±17.57 [-13.33] | -13.29±16.61 [-13.33] |
| P-value [2] |  | 0.3770 | 0.0917 |  |
| **Change from Baseline at Week 12** | -14.31±24.47 [-10.00] | -16.19±17.43 [-16.67] | -18.26±17.63 [-16.67] | -14.86±18.81 [-13.33] |
| P-value [2] |  | 0.0640 | 0.0942 |  |
| **OAB-q - Total health-related quality of life (HRQL) Score** |  |  |  |  |
| **Baseline** | 59.42±19.44 [58.46] | 61.98±19.95 [63.08] | 61.37±20.80 [64.62] | 64.23±20.06 [61.54] |
| **Change from Baseline at Week 4** | 8.63±16.71 [7.69] | 7.01±14.40 [6.15] | 9.77±15.10 [9.23] | 8.61±14.08 [8.46] |
| P-value [2] |  | 0.9824 | 0.3609 |  |
| **Change from Baseline at Week 12** | 13.65±21.36 [10.77] | 12.81±17.12 [10.77] | 15.10±18.05 [13.85] | 11.79±15.16 [10.77] |
| P-value [2] |  | 0.6214 | 0.3099 |  |

LS mean=least square mean; SE=standard error

The values are expressed as mean ± standard deviation [median] or LS mean (SE)

The results of the solifenacin 5mg group were added for exploratory analysis

[1] ANCOVA model with adjustment for the baseline value and gender for the comparison of DA-8010 2.5 mg, 5 mg vs. Placebo

[2] Rank-ANCOVA model with adjustment for the baseline value and gender for the comparison of DA-8010 2.5 mg, 5 mg vs. Placebo